REHOVOT, Israel and JERSEY CITY, New Jersey, April 11 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, announced today it will present multiple posters at the upcoming annual AACR conference in San Diego. The posters will include data on Rosetta Genomics' unique microRNA-based technologies and how they may be applied to develop objective and standardized diagnostic tests and therapeutics for cancer. The event will take place on April 12-16 at the San Diego Convention Center, California.
1. "A microRNA-based diagnostic assay for non-small cell lung cancer"; Sunday April 13, exhibit hall B-F, poster section 7, poster board 6, abstract #946.
Rosetta Genomics has shown that a single microRNA can differentiate squamous from non squamous NSCLC with high sensitivity and specificity. The ability of physicians to accurately differentiate squamous from non-squamous non-small cell lung cancer (NSCLC) is an important treatment guide. Bevacizumab(1), an angiogenesis inhibitor and an important new modality of therapy for non-squamous NSCLC, includes a black-box warning about substantially higher rates of severe or fatal hemorrhage among patients with squamous NSCLC histology compared with non-squamous NSCLC.
2. "Identification of tumor origin using microRNA signature"; Wednesday
April 16, exhibit hall B-F, poster section 2, poster board 1, abstract
#5039. Each year approximately 70,000 patients in the United States are
diagnosed with cancer of unknown primary (CUP). Accurately identifying the
origin of a metastasis can be critical in guiding treatment decisions.
Rosetta Genomics scientists have designed a classifier w
|SOURCE Rosetta Genomics Ltd|
Copyright©2008 PR Newswire.
All rights reserved